Drug discovery & development
CA-051 Clin0 cancer/amputation pain; undisclosed RD osteoarthritis pain
Concentric Analgesics is developing non-opioid therapeutics to provide long-lasting pain relief. While opioids provide pain relief, they are expensive and increase morbidity with patients becoming dependent on the treatment. Concentric’s goal is to provide value-based health care by reducing cost and hastening the return to productivity for patients. Besides avoiding opioid usage, Concentric is creating therapies that are site specific, simple, long-lasting and pain-selective to meet these needs. Concentric’s most advanced investigational product now ready for Phase 3 clinical studies, CA-008, is a water soluble prodrug of capsaicin that desensitizes pain conducting nerve fibers.